Author:
Halbwachs Frédéric,Le Bouar Ronan,Havard Justine,Dietrich Laurent,Wiedemann Jean-Yves,Jacquemin Laurent,Levy Jacques
Publisher
Springer Nature Switzerland
Reference13 articles.
1. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517–24.
2. Wilke I, Witzel K, Munch J, Pecha S, Blankenberg S, Reichenspurner H, et al. High incidence of De novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device. J Cardiovasc Electrophysiol. 2016;27(7):779–84.
3. Authors/Task Force M, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.
4. Writing Committee M, Ommen SR, Mital S, Burke MA, Day SM, Deswal A, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association joint Committee on clinical practice guidelines. Circulation. 2020;142(25):e558–631.
5. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275–444.